Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.81 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL6 | P05231 | 1/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.56 |
| ▸ | GLUL | P15104 | 1/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone Acetate SCHEMBL16144480 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL21546231 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL145794 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL11055358 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL1657958 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL13231 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL145795 | 1.00 | PGR (1.00) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL9802690 | 0.99 | PGR (0.98) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL2272744 | 0.99 | PGR (0.98) | PGRCYP3A4ARF2NR3C1 | |
| Methylprednisolone Acetate SCHEMBL8987980 | 0.99 | PGR (0.98) | PGRCYP3A4ARF2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20210052606-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10857161-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10799514-B2 | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3656385-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | ReveraGen BioPharma, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20130079316-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079316-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2013-03-28 | — | — | US | disclosed |
| US-8334279-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | VALIDUS GENETICS (US) | 2012-12-18 | — | — | US | disclosed |
| US-8207151-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | Validus Biopharma Inc. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207151-B2 | Non-hormonal steroid modulators of NF-κB for treatment of disease | Validus Biopharma Inc. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2246359-A1 | Process for obtaining fluorometholone and intermediates therefor | Crystal Pharma, S.L.U. (ES) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010122096-A1 | PROCESS FOR OBTAINING FLUOROMETHOLONE AND INTERMEDIATES THEREFOR | CRYSTAL PHARMA, S.L.U. (ES) | 2010-10-28 | — | — | WO | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799514-B2 | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885PGR 104/4885CYP3A4 3950/4885 |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885PGR 104/4885CYP3A4 3950/4885 |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885PGR 296/4885CYP3A4 4579/4885 |
| US-20210052606-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885PGR 296/4885CYP3A4 4579/4885 |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 11/4885PGR 104/4885CYP3A4 3950/4885 |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | NFKBIA, NFKB2, IKBKG | NR3C1 10/4885PGR 82/4885CYP3A4 3710/4885 |
| US-10857161-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKB2, NFKBIA, NFKB1 | NR3C1 12/4885PGR 298/4885CYP3A4 4121/4885 |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885PGR 296/4885CYP3A4 4579/4885 |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885PGR 296/4885CYP3A4 4579/4885 |
| US-20130079316-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NR3C1 9/4885PGR 296/4885CYP3A4 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.